(GLOBE NEWSWIRE) – ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, is pleased to announce the appointment of Dominique Vanfleteren as its new Chief Financial Officer (CFO) with immediate effect.
Dominique Vanfleteren has over 25 years of experience in senior finance, operational, control and reporting roles within quoted international biopharmaceutical companies.
Before joining ThromboGenics, Dominique spent 12 years at UCB, a global biopharmaceutical company, where he held a number of international managerial finance positions, the latest being the CFO of UCB’s Asia Pacific Operations, operating from Brussels and Shanghai.
Prior to joining UCB, Dominique worked for GSK during 16 years. He held a number of senior finance positions in Brussels and London, his latest being Finance Director of GSK’s Diversified Healthcare Services Europe.
Dr Patrik De Haes, Chief Executive Officer of Thrombogenics, said: “I am delighted to welcome Dominique Vanfleteren to Thrombogenics as our new CFO. Dominique is bringing significant financial experience from within the biopharmaceutical industry and I am confident that he will prove a great addition to our senior management team as we look to execute our strategy as announced in mid-2014.”
Commenting on his appointment, Dominique Vanfleteren said: “I am very pleased to be joining ThromboGenics and excited to be able to contribute to the Company’s future success based on the further development of JETREA®, as well as on its broader strategy of developing innovative medicines for the treatment of ophthalmic diseases focused on diabetic retinopathy.”
Source:ThromboGenics NV
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.